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INTRODUCTION
The neuronal ceroid lipofuscinoses (NCLs) represent the most
frequent group of inherited neurodegenerative diseases in children,
with an estimated worldwide incidence of 1:14,000 to 1:67,000,
depending on ethnic group and the founder group effect
(Santavuori, 1988; Haltia, 2006; Mole et al., 2011). The NCLs are
characterized by progressive visual and mental decline, motor
disturbances, epilepsy and behavioral changes, ultimately leading
to premature death. These autosomal recessive diseases are caused
by mutations in at least ten genes, including eight conventional
NCL-associated genes (CLN1, CLN2, CLN3, CLN5, CLN6,
CLN7/MFSD8, CLN8 and CTSD/CLN10), and two additional
genes (DNAJC5 and SGSH) (Kousi et al., 2012). Despite this genetic
heterogeneity, the NCLs display a relatively uniform phenotype in
the central nervous system (CNS), characterized by a dramatic loss
of cortical neurons, and accumulation of lysosomal autofluorescent
lipopigments (Jalanko and Braulke, 2009; Mole et al., 2011).
Here, we focus on two NCL diseases: classic infantile NCL
(CLN1) and late infantile variant NCL (CLN5), which are caused
by mutations in CLN1 and CLN5 genes, respectively (Vesa et al.,
1995; Savukoski et al., 1998; Kousi et al., 2012). CLN1 encodes for
PPT1, a soluble lysosomal enzyme that is involved in
depalmitoylation of proteins (Camp and Hofmann, 1993), although
the in vivo substrates of PPT1 are currently unknown (Hellsten et
al., 1995; Jalanko and Braulke, 2009). The CLN5 gene encodes a
soluble lysosomal glycoprotein, implicated recently in endosomal
sorting (Schmiedt et al., 2010; Mamo et al., 2012). CLN5 protein
colocalizes with lysosomal-associated membrane protein (LAMP-
1) (Vesa et al., 2002; Schmiedt et al., 2010), and is expressed by
both neurons and glia (Holmberg et al., 2004; Schmiedt et al., 2012).
We have previously generated Cln1 and Cln5 knockout (ko)
mouse models (Jalanko et al., 2005; Kopra et al., 2004). The Cln1
ko mouse model presents with a severe neurodegenerative disease,
whereas Cln5 ko mice have a much milder phenotype that
progresses more slowly. Both of these mice suffer from several
neurological defects, including motor dysfunction, and exhibit
progressive weight loss and brain atrophy. Neuropathological
analyses show progressive accumulation of autofluorescent storage
material, and a marked glial activation, which precedes neuronal
loss and is most pronounced in the thalamocortical system. Gene
expression profiling of cortical tissue revealed common affected
pathways in Cln1 ko and Cln5 ko mouse models, including
inflammation, cytoskeleton integrity and the neuronal growth cone
assembly (von Schantz et al., 2008). Molecular interaction studies
of NCL proteins have shown that CLN5 appears to interact with
other NCL proteins in vitro, including CLN1/PPT1, CLN2
(tripeptidyl-peptidase 1, TPP1), CLN3, CLN6 and CLN8 (Vesa et
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SUMMARY
Both CLN1 and CLN5 deficiencies lead to severe neurodegenerative diseases of childhood, known as neuronal ceroid lipofuscinoses (NCLs). The
broadly similar phenotypes of NCL mouse models, and the potential for interactions between NCL proteins, raise the possibility of shared or convergent
disease mechanisms. To begin addressing these issues, we have developed a new mouse model lacking both Cln1 and Cln5 genes. These double-
knockout (Cln1/5 dko) mice were fertile, showing a slight decrease in expected Mendelian breeding ratios, as well as impaired embryoid body
formation by induced pluripotent stem cells derived from Cln1/5 dko fibroblasts. Typical disease manifestations of the NCLs, i.e. seizures and motor
dysfunction, were detected at the age of 3 months, earlier than in either single knockout mouse. Pathological analyses revealed a similar exacerbation
and earlier onset of disease in Cln1/5 dko mice, which exhibited a pronounced accumulation of autofluorescent storage material. Cortical demyelination
and more pronounced glial activation in cortical and thalamic regions was followed by cortical neuron loss. Alterations in lipid metabolism in Cln1/5
dko showed a specific increase in plasma phospholipid transfer protein (PLTP) activity. Finally, gene expression profiling of Cln1/5 dko cortex revealed
defects in myelination and immune response pathways, with a prominent downregulation of α-synuclein in Cln1/5 dko mouse brains. The simultaneous
loss of both Cln1 and Cln5 genes might enhance the typical pathological phenotypes of these mice by disrupting or downregulating shared or
convergent pathogenic pathways, which could potentially include interactions of CLN1 and CLN5.
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al., 2002; Lyly et al., 2009). In addition, CLN1 and CLN5 share a
common interaction partner, the F1 subunit of ATP synthase, which
modulates the lipid homeostasis in neurons (Lyly et al., 2008; Lyly
et al., 2009).
The finding that similar functional pathways are affected in these
forms of NCL and the potential interaction of CLNs at the protein
level, raise the possibility that NCL diseases might also be linked
at a molecular level. To gain a deeper insight into the shared
molecular and pathological events behind the NCLs and the
underlying mechanisms of neurodegeneration, we developed a
double-knockout mouse model lacking both Cln1 and Cln5 genes
(Cln1/5 dko). These mice were first analyzed for the possible defects
in embryonic development using induced pluripotent stem (iPS)
cell technology. In the brain, the accumulation of autofluorescence
storage material, presence of astrocytosis, microglial activation and
signs of myelination defects were also investigated and stereological
analyses were performed to study brain atrophy and neuronal loss.
This analysis focused upon the onset and progression of thalamic
and cortical neuron loss, based on the changes we have documented
in mice singly deficient for either Cln1 or Cln5 (Kopra et al., 2004;
Jalanko et al., 2005).
Because previous studies have suggested that CLN1 and CLN5
proteins and diseases are closely related and linked to changes in
cellular lipid homeostasis (Lyly et al., 2008; Schmiedt et al., 2012),
we also conducted plasma lipid profiling of Cln1/5 dko mice. Finally,
gene expression profiling of the Cln1/5 dko mouse cortex was
performed in order to reveal the functional pathways that might
be shared by CLN1 and CLN5 diseases.
RESULTS
Cln1/5 dko iPS cells show impaired embryoid body formation and
delayed differentiation potential
The Cln1/5 dko offspring were viable and fertile. However, the
cross-breeding of Cln1 ko and Cln5 ko mice produced fewer double
homozygous Cln1/5 dko offspring than expected according to
Mendelian ratios (supplementary material Table S1), when the
parents were homozygous for one of the alleles and heterozygous
or homozygous for the other allele. To study a possible defect in
breeding or early development of Cln1/5 dko mice in more detail,
we generated several iPS cell lines from Cln1/5 dko and wild-type
mouse embryonic fibroblasts (MEFs). Two wild-type (clones 15 and
23) and three different Cln1/5 dko (clones 3, 19-2 and 20) iPS cell
clones were selected for further experiments on the basis of their
positive expression of embryonic stem (ES) cell markers SSEA-1,
Nanog, Rex-1, Fgf-4, Esg-1 and E-ras (supplementary material Fig.
S1) and their differentiation potential into embryonic germ layers
(supplementary material Fig. S2). Equal numbers of feeder-free cells
from wild-type and Cln1/5 dko iPS clones were plated in parallel
for embryoid body (EB) formation and the experiment was repeated
three times with different clones. Daily microscopic analyses of
growing EBs showed that between days two and seven the Cln1/5
dko EBs were consistently smaller and more irregularly shaped than
the wild-type EBs (Fig. 1A, an example of one experiment).
Furthermore, the total number of EBs formed from Cln1/5 dko iPS
cell clones appeared to be smaller than those from wild-type clones.
Calculation of the diameter of 7-day-old EBs in different clones
revealed that this reduction in EB size was also statistically
significant (Fig. 1B). This finding was consistent across three
different Cln1/5 dko iPS cell clones. From day seven onwards, both
the size and the shape of EBs became more similar between the
Cln1/5 dko and wild type, indicating problems in early development
of EBs (data not shown). The formed EBs were then plated on
gelatin-coated plates to allow spontaneous differentiation and cell
outgrowth from EBs. Microscopic analyses showed that cellular
outgrowth from Cln1/5 dko EBs was much slower than from the
wild-type EBs. On day three after plating, wild-type EBs had lost
their round shape and cellular growth was seen all over the plates.
In contrast, Cln1/5 dko EBs were still round and cellular growth
was only detected close to the EBs (Fig. 1C), indicating that
spontaneous cell differentiation was also delayed. These possible
defects in early development could explain the detected decrease
in the number of the born offspring of Cln1/5 dko mice.
Cln1/5 dko mice display an early neuropathological phenotype
The Cln1/5 dko mice presented with a rapidly progressing NCL
disease phenotype, already displaying severe symptoms, including
seizures and motor dysfunction, by the age of 3 months, which was
TRANSLATIONAL IMPACT
Clinical issue
Neuronal ceroid lipofuscinoses (NCLs) are monogenic neurodegenerative
diseases that offer well-established models with which to study the molecular
events underlying neurodegeneration. Although there are at least ten different
genes that underlie NCLs, the clinical phenotype is usually similar, and is
generally characterized by progressive loss of vision, mental and physical
decline, epileptic seizures and premature death. The similar phenotypes
observed between genetically different NCL mouse models, and the potential
for interactions between different NCL proteins, suggest that shared or
convergent disease mechanisms might underlie the different forms of the
disease. Analysis of these disease mechanisms should help to identify
biomarkers that could be used to monitor the efficacy of therapeutic
strategies. No curative therapies for NCLs are currently available, but several
promising approaches are being investigated, particularly for the forms of the
disease caused by deficiency of soluble lysosomal proteins such as CLN1 and
CLN5, which were investigated in this study. 
Results
The authors developed a mouse model lacking both Cln1 and Cln5 genes to
study disease mechanisms in the NCLs. The consequences of combined
deficiency of CLN1 and CLN5 are of interest because these proteins might
interact, and common disease mechanisms have been suggested. The authors
show that deficiency of both Cln1 and Cln5 genes leads to a more severe NCL
phenotype in mice than does deficiency of either gene alone. Cortical
demyelination, and pronounced glial activation in cortical and thalamic
regions, was followed by cortical neuron loss. Specifically, microglial activation
and lipid abnormalities were highlighted. The authors also identified several
dysregulated proteins that might have value as biomarkers. Finally, the authors
show that expression of α-synuclein was decreased in the brains of Cln1/5
double-knockout mice, an interesting finding that warrants further
investigation.
Implications and future directions
This study demonstrates the use of a new Cln1/5 double-knockout mouse for
identifying disease-modifying factors in NCL and other neurodegenerative
diseases. Further studies using this model will help to more accurately identify
the molecular defects underlying NCLs associated with CLN1 or CLN5
mutations, and to identify disease biomarkers. Deeper understanding of the
biochemical and molecular cascade of events relevant to the pathogenesis of
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much earlier than Cln1 ko mice (5 months) or Cln5 ko mice (8
months) (Jalanko et al., 2005; Kopra et al., 2004) (data not shown).
The onset of the symptoms and the progression of the disease were
slightly variable among the Cln1/5 dko mice. All three mouse
models showed a significant reduction in body weight at the age
of 3 months compared with wild-type controls (supplementary
material Fig. S3). Cln1/5 dko mice were euthanized at the age of 3
months due to their severe disease phenotype.
The accumulation of autofluorescent lipopigments is a key
pathological feature of all forms of NCL and was analyzed in Cln1
ko, Cln5 ko, Cln1/5 dko and wild-type control mice via confocal
microscopy. Increased amounts of punctate autofluorescent
material were observed in the thalamus and cortex of 3-month-
old Cln1 ko, whereas in Cln5 ko and in wild-type controls it was
almost absent at this age. In contrast, Cln1/5 dko mice displayed
a much more pronounced accumulation of autofluorescent material
(Fig. 2A), and this was already seen in 1-month-old Cln1/5 dko
mice (data not shown). Thresholding image analysis showed
elevated, but not significant, levels of autofluorescent material in
the cortex and thalamus of Cln1 ko and Cln1/5 dko mice, compared
with wild type (Fig. 2B).
The ultrastructural appearance of the storage material is specific
to individual forms of NCL and it differs between these forms
(Haltia, 2003; Tyynelä et al., 1993; Tyynelä et al., 2004). On a mixed
C57BL background, Cln1 ko mice show accumulation of granular
osmiophilic deposits (GRODs) in the brain and other tissues,
whereas in Cln5 ko mice, the storage material displays rectilinear,
curvilinear and fingerprint profiles (Jalanko et al., 2005; Kopra et
al., 2004). In a C57BL/6JRcc background, the ultrastructure of the
storage material in Cln1 ko mice was composed of GRODs, and in
Cln5 ko the storage material varied from rectilinear to fingerprint-
like (Fig. 2C, panels 5 and 6). Electron microscopic analysis of 3-
month-old Cln1/5 dko mouse brains revealed marked accumulation
of GRODs within cortical and thalamic neurons (Fig. 2C, panels 1
and 3). The ultrastructure of the storage deposits was almost
identical to that seen in Cln1 ko mice (Fig. 2C, panel 5), but the
storage deposits were much more abundant in the dko mice
compared with either of the single ko mice. Within cortical
neurons, tiny electron-dense grains were visible inside these
GRODs (Fig. 2C, panel 2), whereas in the thalamus, the storage
bodies appeared to be more electron-dense than in the cerebral
cortex (Fig. 2C, panels 3 and 4). Higher magnification shows that
the GRODs are surrounded by a double membrane (Fig. 2C, panels
2 and 4).
Early immune response is enhanced in Cln1/5 dko mice
Localized astrocytosis and microglial activation has been reported
to occur both in Cln1 ko and Cln5 ko mice (Bible et al., 2004; von
Schantz et al., 2009; Schmiedt et al., 2012). To investigate the
extent of astrocytosis in Cln1/5 dko mice we stained brain
sections from 3-month-old mice for the astrocytic marker glial
fibrillary acidic protein (GFAP), and compared them to Cln5 ko,
Cln1 ko and wild-type mice at the same age. We concentrated
our analysis upon primary somatosensory barrelfield cortex
(S1BF) and thalamic ventral posteromedial nucleus/ventral
posterolateral nucleus (VPM/VPL), which relays sensory
information to this cortical subfield, because both of these
structures are consistently severely affected in NCL mouse models
(Cooper, 2010). As previously reported (von Schantz et al., 2009),
only a few scattered GFAP-positive astrocytes were present in
VPM/VPL of young Cln5 ko mice, but many more intensely
stained astrocytes were present in the thalamic nucleus of young
Cln1 ko mice. However, GFAP staining of the corresponding brain
region in Cln1/5 dko mice revealed a more profound astrocytosis,
significantly greater than that seen in Cln5 ko mice and modestly
increased compared with Cln1 ko mice, with the VPM/VPL and
surrounding nuclei of Cln1/5 dko mice completely filled with
hypertophic and intensely GFAP-immunoreactive astrocytes (Fig.
3A). Comparing single- and double-knockout mice revealed a
similar relationship in degree of staining in the S1BF region of
the cortex, showing pronounced astrocytosis all across cortical
laminae in Cln1 ko mice, but with additional bands of more
intensely and darkly stained astrocytes in laminae II-IV and VI
in Cln1/5 dko mice (Fig. 3A). Thresholding image analysis
confirmed the significant increase in GFAP immunoreactivity in
VPM/VPL and S1BF regions of Cln1 ko and Cln1/5 dko brains,
compared with the wild-type brains (Fig. 3C).
Activated microglia can be detected by the expression of CD68,
a lysosomal/endosomal membrane glycoprotein (Holness et al.,
1993). In wild-type mice, palely stained CD68-positive microglia
were present in most CNS regions, but at 3 months of age
widespread CD68 immunoreactivity was present in the brains of
Fig. 1. Impaired EB formation and differentiation of Cln1/5 dko iPS cells.
(A)Microscopic images reveal the smaller size and more irregular shape of
Cln1/5 dko EBs compared with wild-type EBs on day seven. (B)Statistical
analysis of EB diameters shows significant difference in the EB size of wild-type
and Cln1/5 dko clones. Columns present average EB size (n≥40); error bars
represent s.e.m. *P<0.05, ***P<0.001. (C)EBs from 7-day-old mice were plated
on gelatin-coated plates for spontaneous differentiation. Images show slower
cellular outgrowth from Cln1/5 dko EBs compared with wild-type EBs,
indicating delayed spontaneous differentiation potential of Cln1/5 dko EBs.
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all three mutant mice, most notably in the thalamic relay nuclei,
lateral and medial geniculate nuclei, cortical regions (S1BF), the
subiculum and selected hippocampal subfields, the globus pallidus
and substantia nigra. Focusing upon the S1BF and VPM/VPL
regions, microglial activation was consistently more advanced in
this thalamic relay nucleus than in its corresponding cortical target
region (Fig. 3B). Consistent with our recent findings (Schmiedt et
al., 2012), 3-month-old Cln5 ko mice already showed evidence of
microglial activation, with CD68-stained microglia displaying
larger and more darkly stained cell soma than in wild-type controls.
This phenotype was more pronounced in Cln1 ko mice, with a
subset of microglia displaying a brain-macrophage-like
morphology, but was exacerbated further in Cln1/5 dko mice, in
which the entire thalamus was filled with intensely stained CD68-
positive microglia with swollen cell soma and only very short cell
processes (Fig. 3B). An elevated level of CD68 staining was already
detectable in both thalamus and cortex of Cln1/5 dko mice at 1
month of age (supplementary material Fig. S4). Thresholding
image analysis verified this widespread and significant microglial
activation in the S1BF of Cln1/5 dko mouse brains, compared with
wild-type mice (Fig. 3D). Due to a higher degree of variation, this
elevated CD68 expression did not exceed the significant levels of
microglial activation in the VPM/VPL or S1BF regions of Cln5 ko
mice that we have previously reported (Schmiedt et al., 2012).
Disturbed cortical myelination in Cln1/5 dko mice
Disturbed myelination has previously been described in Cln5 ko
mice (Kopra et al., 2004; von Schantz et al., 2009; Schmiedt et al.,
2012), but has not been studied in Cln1 ko mice. Immunostaining
for myelin basic protein (MBP), a main protein constituent of the
myelin sheath, revealed no overt disruption of white matter
structures in 1- and 3-month-old Cln5 ko mice, but the superficial
laminae of S1BF contained fewer MBP-positive fibers (Schmiedt
et al., 2012). Performing similar analyses in this study revealed
more pronounced effects on MBP staining in this brain region of
Cln1/5 dko mice, compared with either Cln1 ko or Cln5 ko mice.
Compared with wild-type controls, 1-month-old Cln1/5 dko
mice displayed fewer MBP immunopositive fibers running
dorsoventrally and horizontally through the superficial laminae
(laminae II and III) of S1BF (Fig. 4A). By 3 months of age, all three
mutant mouse models showed fewer MBP-positive fibers in the
superficial laminae of S1BF compared with wild-type controls
(Fig. 4B).
Cln1/5 dko mice show neuron loss in cortical lamina VI at 3 months
of age
Cortical atrophy is a common feature of all human and murine
NCLs (Cooper et al., 2006), but occurs relatively late in disease
progression. In order to determine whether this phenotype was
Fig. 2. Accumulation of autofluorescent storage material in
cerebral cortex and thalamus. (A)Confocal images of tissue
sections from the cortex and thalamus show markedly
increased autofluorescence in 3-month-old Cln1/5 dko mice.
Scale bar: 100 μm. (B)Thresholding image analysis revealed
higher levels, although not significantly, of autofluorescent
storage material in the cortex and thalamus of Cln1/5 dko
mice. (C)Electron micrographs of the storage material in the
Cln1/5 dko, Cln1 ko and Cln5 ko brains. (C1)Cortical neuron of
3-month-old Cln1/5 dko mouse shows numerous storage
bodies (indicated by arrows) and mitochondria in the
perinuclear area. (C2)At higher magnification, ultrastructure of
the neuronal storage material is clearly visible, showing typical
granular osmiophilic deposits, GRODs, with tiny grains inside.
The storage material is surrounded by a double membrane.
(C3)Within the thalamus of 3-month-old Cln1/5 dko mice,
some neurons were loaded with storage bodies, which were
more electron-dense than those in the cerebral cortex.
(C4)Higher magnification of the thalamic storage bodies
shows typical GRODs surrounded by a double membrane.
(C5)Ultrastructure of the storage material within cortical
neurons of 3-month-old Cln1 ko mice closely resembles the
GRODs seen in the cerebral cortex of Cln1/5 dko mice,
although the storage deposits are less abundant in Cln1 ko
mice than in Cln1/5 dko mice at this age. (C6)In the cortex of 3-
month-old Cln5 ko mice, the neuronal storage material is
composed of membranous profiles with rectilinear and
fingerprint-like features. Magnification 10,000× in C1 and C3;
40,000× in C2 and C4-6. Scale bars: 2 μm (C1,C3); 1 μm (C2,C4-
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already apparent in 3-month-old Cln1/5 dko mice, we carried out
thickness measurements in Nissl-stained sections through primary
motor (M1), S1BF, primary visual (V1) and lateral entorhinal (LEnt)
regions, as representative cortical regions that serve different
functions. Compared with wild-type controls, no significant
thinning was observed in any cortical region of 3-month-old
Cln1/5 dko brains or in age-matched Cln1 ko mice (supplementary
material Fig. S5A). As reported previously (von Schantz et al., 2009),
the cortical thickness of S1BF, M1 and V1 in Cln5 ko mice was
significantly increased at this age.
We next conducted a stereological analysis of regional volumes
in Cln1 ko, Cln5 ko, Cln1/5 dko and wild-type brains at 3 months
Fig. 3. Increased astrocytosis and widespread
microglial activation in the thalamocortical
system of 3-month-old Cln1/5 dko mice.
(A)Immunohistochemical staining for the
astrocytic marker GFAP in 3-month-old wild-type,
Cln5 ko, Cln1 ko and Cln1/5 dko mice.
Representative images from VPM/VPL and S1BF
show pronounced and widespread astrocytosis in
Cln1 ko and Cln1/5 dko brains, and elevated GFAP
expression in the Cln5 ko brain. Insets from Cln5
ko, Cln1 ko and Cln1/5 dko show the morphology
of GFAP-positive hypertrophic astrocytes with
enlarged soma and thickened processes.
(B)Immunohistochemical staining for the
microglial marker CD68 in 3-month-old wild-type,
Cln5 ko, Cln1 ko and Cln1/5 dko mice. Widespread
activation of microglia in VPM/VPL and S1BF was
evident in all three mouse models, being most
elevated in Cln1 ko and Cln1/5 dko brains. Insets
from Cln5 ko, Cln1 ko and Cln1/5 dko show the
morphology of activated CD68-positive microglia,
with swollen soma and shortened processes. Scale
bars: 50 μm (insets) or as indicated.
(C)Quantification of increased microglial
activation (CD68 immunoreactivity) and (D)
astrocytosis (GFAP immunoreactivity) in 3-month-
old Cln1/5 dko mice. Thresholding image analysis
confirms the significantly increased GFAP
expression in the thalamic VPM/VPL and cortical
S1BF regions of Cln1/5 dko mouse brain,
compared with wild-type controls. CD68
expression was significantly increased in the S1BF
of Cln1/5 dko mouse brain compared with wild-
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of age. Cavalieri estimates of regional volumes revealed no
significant atrophy of the cortex or hippocampus of the Cln1/5 dko
mice at this age. Consistent with the thickness measurements, the
cortical volumes of Cln5 ko mice were significantly increased
compared with the wild-type controls. In addition, the hippocampal
volume was significantly increased in the Cln5 ko brain
(supplementary material Fig. S5B).
To investigate the extent of neuron loss in Cln1/5 dko mice,
we conducted optical fractionator estimates of the number of
Nissl-stained VPM/VPL neurons and of neuron populations in
three cortical laminae of S1BF: lamina IV granule neurons that
receive thalamic innervations; projection neurons in lamina V;
and lamina VI neurons that supply feedback to the thalamus. We
chose these regions because they are characteristically vulnerable
in mouse models of NCL (Pontikis et al., 2005; Weimer et al.,
2006; Kielar et al., 2007; Partanen et al., 2008). This analysis
revealed consistently fewer neurons in all brain regions of 3-
month-old Cln1/5 dko mice, than in mice deficient for either Cln1
or Cln5 alone. However, it was only in lamina VI of S1BF of 3-
month-old Cln1/5 dko mice that this neuron loss was statistically
significant (Fig. 5).
Lipid profiles in Cln1/5 dko mice plasma show significant increase
in phospholipids and PLTP activity
Alterations in systemic lipid metabolism have been reported in both
Cln1 ko (Lyly et al., 2008) and Cln5 ko mice (Schmiedt et al., 2012).
Therefore, we wanted to assess possible lipid metabolism changes
when both Cln1 and Cln5 are deleted. Plasma cholesterol,
phospholipids, triglycerides, apoA-1 and the activity of
phospholipid transfer protein (PLTP) in 1-month-old female mice
were analyzed from wild-type, Cln5 ko, Cln1 ko and Cln1/5 dko
mice. Phospholipid levels in Cln1/5 dko mice were significantly
increased, whereas cholesterol, triglyceride and apoA-1 levels were
slightly elevated compared with wild-type controls (Fig. 6A). Total
cholesterol levels were significantly decreased in Cln5 ko plasma,
as well as in Cln1 ko plasma, as reported previously (Lyly et al.,
2008). However, in this study, the cholesterol levels in Cln5 ko mice
did not significantly differ from those of wild-type mice, as
previously reported (Schmiedt et al., 2012). Increased plasma
PLTP activity is suggested to be associated with increased
cholesterol levels (Colhoun et al., 2001), and PLTP activity was
Fig. 4. Defective myelination in the cortical laminae of Cln5 ko, Cln1 ko and
Cln1/5 dko mouse brain. (A)Immunohistochemical staining with MBP
revealed loss of MBP immunopositivity in Cln1/5 dko cortex at the age of 1
month, especially in the most superficial laminae of S1BF (laminae II and III).
(B)All mouse models showed less MBP immunopositivity in the superficial
laminae of S1BF than wild-type mice at the age of 3 months. Scale bar: 100 μm.
Fig. 5. Early loss of cortical neurons in Cln1/5 dko mice.
Unbiased optical fractionator estimates of the number of Nissl-
stained neurons of 3-month-old mice in S1BF lamina IV (A),
lamina V (B), lamina VI (C) and VPM/VPL (D) revealed significant
loss of neurons in S1BF lamina VI of Cln1/5 dko brain. No
significant loss of cortical S1BF neurons in laminae IV and V, or
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indeed significantly increased in Cln1/5 dko mice compared with
wild-type mice (Fig. 6B). However, plasma PLTP activity in Cln1
ko and Cln5 ko mice did not differ from that of wild-type controls
and therefore did not support our previous results (Lyly et al., 2008;
Schmiedt et al., 2012).
To verify the detected lipid changes in Cln1/5 dko mice, we also
analyzed the distribution of lipids and apoA-1 in lipoprotein
fractions. Cholesterol levels were clearly elevated in high density
lipoprotein (HDL) particles and slightly decreased in very low
density lipoprotein (VLDL) particles of Cln1/5 dko plasma
(supplementary material Fig. S6A). In addition, the elevated PLTP
activity led to enhanced phospholipid transfer from the VLDL pool
to HDL pool (supplementary material Fig. S6A). ApoA-1 was clearly
elevated in both small (pre-β-HDL) and large HDL particles
(supplementary material Fig. S6B), indicating increased PLTP
activity, which is known to induce the formation of lipid-poor pre-
β-HDL particles (Siggins et al., 2007). Furthermore, elevated
triglyceride levels were found in VLDL particles (supplementary
material Fig. S6C). Together, these results suggest a change in
systemic lipid homeostasis in Cln1/5 dko mice.
Gene expression profiling of the Cln1/5 dko mouse cortex
Global gene expression analysis of ~45,000 transcripts from 1-
month-old Cln1/5 dko cortex revealed statistically significant
upregulation of 24 genes (Table 1) and downregulation of 31 genes
(Table 2). The most upregulated gene was cyclase-associated
protein 1 (Cap1, 1.9-fold), and the most downregulated gene was
α-synuclein (Snca, −177.2-fold). Other upregulated genes included
complement subcomponents C1qb (C1qb, 1.6-fold) and C1qc
(C1qc, 1.4-fold), Fc receptor homolog S (Fcrls, 1.6-fold) and glial
Fig. 6. Lipid profile analysis from 1-month-old
wild-type, Cln1 ko, Cln5 ko and Cln1/5 dko mouse
plasma. Cholesterol (Chol), phospholipid (PL),
triglyceride (Trig) and apoA-1 levels (A) and PLTP
activity (B) were determined from individual wild-
type, Cln1 ko, Cln5 ko and Cln1/5 dko mouse plasma
samples. PL levels, as well as PLTP activity, were
significantly increased in Cln1/5 dko mice. Values
plotted as mean + s.e.m. *P<0.05, **P<0.01,
***P<0.001.
Table 1. Upregulated genes in 1-month-old Cln1/5 dko cortex 
Probe ID Symbol Description Adj. P-value FC 
3440343 Cap1 CAP, adenylatecyclase-associated protein 1 (yeast) 2.88E-03 1.9 
580332 C1qb Complement component 1, q subcomponent, beta polypeptide 5.87E-03 1.6 
940541 Fcrls Fc receptor-like S, scavenger receptor 3.03E-02 1.6 
1450139 Gfap Glial fibrillary acidic protein 1.63E-03 1.5 
3710170 C1qc Complement component 1, q subcomponent, C chain 3.03E-02 1.4 
2710367 Ntsr2 Neurotensin receptor 2 2.68E-02 1.4 
2630543 Ndrg2 N-myc downstream regulated gene 2 1.79E-03 1.4 
6110736 B2m Beta-2 microglobulin 1.38E-02 1.4 
5570253 B2m Beta-2 microglobulin 1.58E-02 1.3 
7150026 Fam171b Family with sequence similarity 171, member B 1.66E-02 1.3 
940338 S100a1 S100 calcium binding protein A1 1.25E-02 1.3 
6350044 Slc2a1 Solute carrier family 2 (facilitated glucose transporter), member 1 2.14E-02 1.3 
2650672 Mll1 Myeloid/lymphoid or mixed-lineage leukemia 1 3.89E-02 1.2 
7050487 Cd63 CD63 antigen 2.24E-02 1.2 
5670328 Atp1b2 ATPase, Na+/K+ transporting, beta 2 polypeptide 3.89E-02 1.2 
2340349 Aldh2 Aldehyde dehydrogenase 2, mitochondrial 3.89E-02 1.2 
3190301 Aak1 AP2 associated kinase 1 2.88E-02 1.1 
1300327 Capzb Capping protein (actin filament) muscle Z-line, beta 3.21E-02 1.1 
1170768 Cox6a1 Cytochrome c oxidase, subunit VI a, polypeptide 1 3.03E-02 1.1 
6180465 Ddx17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 4.11E-02 1.1 
1510133 Cox6a1 Cytochrome c oxidase, subunit VI a, polypeptide 1 3.43E-02 1.1 
2570669 Mapk1 Mitogen-activated protein kinase 1 3.51E-02 1.1 
620470 Gm10224 Predicted pseudogene 10224 3.66E-02 1.1 
4060274 Dlgap1 Discs, large (Drosophila) homolog-associated protein 1 4.91E-02 1.1 
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fibrillary acidic protein (GFAP, 1.5-fold). Downregulation of
oligodendrocytic myelin and paranodal and inner loop protein
(Opalin, −1.8-fold), as well as other myelin genes (myelin and
lymphocyte protein Mal, −1.6-fold; myelin associated glycoprotein
Mag, −1.6-fold; myelin oligodendrocyte glycoprotein Mog, −1.5-
fold; proteolipid protein Plp1, −1.2-fold; and myelin basic protein
Mbp, −1.2-fold) was also observed. The Ppt1 (Cln1) gene was also
downregulated (−5.1-fold), whereas downregulation of the Cln5
gene was not observed, due to the lack of a specific probe in the
gene expression array.
Analyses of biological pathways are often more informative than
single gene changes. In order to characterize the affected pathways
in 1-month-old Cln1/5 dko mice, and to compare them to the
existing data from Cln1 ko and Cln5 ko mice, we performed a
DAVID functional annotation clustering analysis. We discovered
that pathways related to the immune response were upregulated,
whereas pathways related to myelin ensheathment and transmission
of nerve impulse were downregulated (Table 3). These results are
in line with the published defects in nerve ensheathment and
myelination, and upregulation of inflammation-associated
pathways in Cln1 ko mice and neurons (Ahtiainen et al., 2007; von
Schantz et al., 2008). A common gene upregulated in all three
models (Cln1 ko, Cln5 ko and Cln1/5 dko) is Cap1, a gene crucial
for the neuronal growth cone-cytoskeletal dynamics (Ahtiainen et
al., 2007; von Schantz et al., 2008; this study). Our results from
immunohistochemical studies indicate enhanced glial activation
and defective myelination in Cln1/5 dko brain, and are thus
consistent with the gene expression analysis data.
The downregulation of the most differentially expressed gene
between the two genotypes (wild-type and Cln1/5 dko), Snca, was
further evaluated with quantitative real-time reverse-transcriptase
PCR (RT-PCR). The results support the microarray data,
demonstrating almost complete lack of Snca expression in the
Cln1/5 dko cortex (supplementary material Fig. S7A).
Decreased α-synuclein expression in Cln1/5 dko mouse cortex
As a novel finding, gene expression profiling indicated a pronounced
downregulation of α-synuclein gene expression in the Cln1/5 dko
Table 2. Downregulated genes in 1-month-old Cln1/5 dko cortex 
Probe ID Symbol Description Adj. P-value FC 
5130372 Snca Synuclein, alpha 0.00E+00 –177.2 
5130202 Snca Synuclein, alpha 0.00E+00 –84.4 
730372 Snca Synuclein, alpha 1.18E-03 –7.3 
990064 Ppt1 Palmitoyl-protein thioesterase 1 1,31E-02 –5,1 
380259 Mal Myelin and lymphocyte protein, T cell differentiation protein 3.50E-02 –1.6 
4780010 Mal Myelin and lymphocyte protein, T cell differentiation protein 3.76E-03 –1.6 
160465 Mag Myelin-associated glycoprotein 1.24E-03 –1.6 
6760255 Evi2a Ecotropic viral integration site 2a 3.21E-02 –1.6 
6400053 Mog Myelin oligodendrocyte glycoprotein 3.50E-02 –1.5 
290044 Gamt Guanidinoacetatemethyltransferase 4.46E-02 –1.5 
620070 Mog Myelin oligodendrocyte glycoprotein 1.28E-02 –1.5 
2570228 Ugt8a UDP galactosyltransferase 8A 3.89E-02 –1.5 
4120360 Tspan2 Tetraspanin 2 1.25E-02 –1.5 
2810706 Fa2h Fatty acid 2-hydroxylase 1.83E-02 –1.4 
1850435 Cldn11 Claudin 11 2.72E-03 –1.4 
6940079 Cnp 2,3-Cyclic nucleotide 3 phosphodiesterase 2.14E-02 –1.4 
3180750 Dbp D site albumin promoter binding protein 1.51E-02 –1.4 
6180411 Gltp Glycolipid transfer protein 3.50E-02 –1.3 
7040044 Trf Transferrin 3.89E-02 –1.3 
1770468 Adssl1 Adenylosuccinatesynthetase-like 1 2.69E-02 –1.3 
4490554 Sema4a Sema domain, Ig domain, TM domain and semaphorin domain 4A 4.77E-02 –1.3 
6960026 Dbndd2 Dysbindin (dystrobrevin binding protein 1) domain containing 2 5.35E-04 –1.2 
1780221 Plp1 Proteolipid protein (myelin) 1 2.72E-03 –1.2 
7000343 Lass2 LAG1 homolog, ceramide synthase 2 3.89E-02 –1.2 
1450646 Mbp Myelin basic protein 3.50E-02 –1.2 
2900291 Nudc Nuclear distribution gene C homolog (Aspergillus) 3.66E-02 –1.2 
5050577 Ctps Cytidine 5-triphosphate synthase 2.14E-02 –1.2 
6620603 Tecr Trans-2,3-enoyl-CoA reductase 1.51E-02 –1.2 
3420538 Degs1 Degenerative spermatocyte homolog 1 (Drosophila) 3.89E-02 –1.1 
830397 Ptn Pleiotrophin 3.66E-02 –1.1 
7610246 Slitrk5 SLIT and NTRK-like family, member 5 3.57E-02 –1.1 
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mouse cortex. To validate this result at the protein level, we
performed western blotting of cortical and cerebral (whole brain apart
from the cerebellum) lysates from 1- and 3-month-old mice. In
cortical lysates from 3-month-old Cln1/5 dko mice, the expression
of full-length (19 kDa) α-synuclein was completely absent compared
with wild-type controls (Fig. 7A). In the cerebrum, the expression
of α-synuclein protein was absent in three out of five Cln1/5 dko
lysates, whereas two out of five had normal α-synuclein levels (Fig.
7B). Similarly, no expression of α-synuclein was observed in the 1-
month-old Cln1/5 dko mouse cortex (supplementary material Fig.
S7B) and expression was reduced in the cerebrum of Cln1/5 dko
mice (supplementary material Fig. S7B). Quantification of α-
synuclein expression levels showed significant reduction in α-
synuclein expression in both cortex and cerebrum of 1-
(supplementary material Fig. S7D) and 3-month-old (Fig. 7C) Cln1/5
dko mice compared with wild-type controls. The cerebrum of 1- and
3-month-old Cln1 ko and Cln5 ko mice expressed unchanged α-
synuclein levels (supplementary material Fig. S8).
Table 3. Up- and downregulated pathways in 1-month-old Cln1/5 dko cortex 
Ontology Genes Benjamini* P-value FC 
Upregulated pathways 
MHC class I protein complex 5 2.43E-03 1.68E-05 31 
MHC protein complex 5 3.22E-03 4.44E-05 25 
Defense response 11 1.35E-02 2.35E-05 5 
Antigen processing and presentation of peptide antigen via MHC class  4 1.46E-02 5.11E-05 53 
Downregulated pathways 
Myelin sheath 3 7.27E-03 1.67E-04 –145.4 
Transmission of nerve impulse 7 1.97E-02 1.50E-05 –12.3 
*Benjamini-Hochberg method was used for multiple hypothesis testing correction of the P-values. FC, fold change. 
Fig. 7. Western blot analysis of α-synuclein levels in 3-month-
old wild-type and Cln1/5 dko mouse brain. (A)In the cortex, α-
synuclein protein expression was completely absent in Cln1/5
dko brains compared with wild-type brains. (B)α-Synuclein
expression in cerebral lysates was absent in three out of five
Cln1/5 dko samples. (C)Quantification of α-synuclein protein
expression. Densitometric analysis shows a significant decrease
in the expression of α-synuclein in the Cln1/5 dko cortex and
cerebrum compared with the wild-type brains.
(D)Immunohistochemical analysis of α-synuclein in 3-month-old
wild-type, Cln1 ko, Cln5 ko and Cln1/5 dko brains. There was a
marked reduction in α-synuclein staining in the neuropil of
Cln1/5 dko cerebral cortex. Hippocampal α-synuclein staining
was also decreased in the Cln1/5 dko brain. In addition, slightly
reduced α-synuclein staining was observed in the cortical
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α-synuclein protein expression levels were also investigated by
immunohistochemical staining in 3-month-old wild-type, Cln1 ko,
Cln5 ko and Cln1/5 dko brain sections (Fig. 7D). We observed
markedly reduced α-synuclein staining in the cortical neuropil, as
well as some reduction in the hippocampus of Cln1/5 dko mice.
In Cln5 ko mice, cortical and hippocampal α-synuclein
immunoreactivity was also somewhat reduced. These results
support our western blot findings that show weak α-synuclein
expression in the cortex and close to normal expression levels in
the cerebrum of a subset of Cln1/5 dko mice.
DISCUSSION
Characterization of NCL mouse models is essential for obtaining
new information about disease progression and for a better
understanding of the mechanisms behind the disease. In this study,
we have created a new Cln1/5 dko mouse model and provide a
detailed description of neuropathological events, focusing on the
consequences of a deficiency in both of these genes. In general, the
Cln1/5 dko mice exhibit an earlier onset and more severe
neurological and neuropathological phenotypes than was seen in
the individual Cln1 ko or Cln5 ko mouse models (summarized in
Table 4).
Possible developmental defects are associated with Cln1/5deficiency
Despite their severe neurological phenotype, the Cln1/5 dko mice
are viable, but produce fewer double homozygous offspring than
expected according to Mendelian ratios, probably due to reduced
fertility. Furthermore, our data show that EB formation of Cln1/5
dko mice iPS cells is impaired, and further differentiation of EBs
is much slower than that of wild-type controls. This could
indicate that simultaneous deficiency of Cln1 and Cln5 genes
might impact fetal survival in mice, seen as a lower number of
offspring. Indeed, similar findings have previously been shown
to be specifically associated with the iPS cells derived from
another lysosomal storage disease, mucopolysaccharidosis VII
(Meng et al., 2010). Homozygous mutations of both Cln1 and Cln5
genes in human patients have not been reported, but CLN1
patients with homozygous mutation of Cln1 gene accompanied
by an extra heterozygous mutation in the Cln5 gene are known
(Kousi, 2012). Our results indicate that the simultaneous
dysfunction of both Cln1 and Cln5 genes worsens the clinical
picture in mice, and in vitro experiments also suggest partial
lethality. Considering these data, it is possible that the
homozygous mutations in both CLN1 and CLN5 genes might be
lethal in humans and therefore might not be detected in analyses
of NCL disease-causing mutations.
Glial activation and defective myelination precede
neurodegeneration in Cln1/5 dko brain
Astrocytosis has long been considered a hallmark of
neurodegenerative changes. Significant upregulation of GFAP is
evident in immunohistochemistry and microarray studies of Cln1
ko and Cln5 ko mice (Elshatory et al., 2003; von Schantz et al., 2008;
von Schantz et al., 2009). Our current data are consistent with these
findings, with increased levels of astrocytosis in every region of
the Cln1/5 dko mice CNS, which is already strong at the age of 3
months. Microglial activation was also widespread in 3-month-old
Cln1/5 dko CNS, and was especially pronounced in the
thalamocortical system. Microglia are the brain’s intrinsic immune
cells and play important roles in injury and neurodegenerative
diseases (Perry et al., 2010). Microglia serve as damage sensors,
and injury or pathological processes lead to activation of these cells
from their resting state. Thus, this microglial activation in Cln1/5
dko might be a response to increased cellular damage caused by
storage material accumulation and lysosomal enlargement.
Reactive astrocytes and microglia often accompany neuronal loss
and might be indicative of neuronal dysfunction (Gehrmann et al.,
1995; Macauley et al., 2011). Indeed, in mouse and large animal
models of NCL, glial activation invariably precedes neuron loss and
is the most accurate predictor of where neurons are subsequently
lost (Cooper, 2010). In this respect, the more enhanced reactive
phenotype of Cln1/5 dko mice suggests that neuron loss would also
be more pronounced if these mice were allowed, or able, to survive
longer. Our investigation of neuron survival in these mice does
reveal an earlier onset of neuron loss, although this did not reach
significance in most brain regions. Nevertheless, it is evident that
deficiency of both Cln1 and Cln5 clearly exacerbates this
characteristic and early neuropathological feature of NCL disease
progression.
Neuron loss begins in cortical lamina VI in Cln1/5 dko mice
In the Cln1 ko mouse model, neuron loss begins in the thalamus
and only subsequently occurs in the corresponding cortical region
(von Schantz et al., 2009). In contrast, in Cln5 ko mice, neuron loss
begins in the cortex and only subsequently occurs in thalamus (von
Schantz et al., 2009). In Cln1/5 dko, the only significant neuron loss
was observed in cortical lamina VI of S1BF, suggesting that, as in
Cln5 ko mice, neuron loss in the thalamocortical system of Cln1/5
dko mice also occurs first in the cortex at the age of 3 months of age.
It is perhaps surprising that more pronounced neuron loss was not
seen in these Cln1/5 dko mice, but it should be remembered that
this is the earliest documented incidence of significant neuron loss
in one of these mouse models and has already occurred at a relatively
Table 4. Overview of neurological and neuropathological changes in Cln1 ko, Cln5 ko and Cln1/5 dko mouse models 
Parameter Cln1 ko Cln5 ko Cln1/5 dko 
Onset of symptoms 5 months 8 months 3 months 
Phenotype Motor abnormalities, seizuresa Motor abnormalities, seizuresb Motor abnormalities, seizurese 
Ultrastructure of storage material GRODa Rectilinear, curvilinear, fingerprintb GRODe 
Onset of neuron loss Thalamus (4 months)c Cortex lam IV and V (4 months)c Cortex lam VI (3 months)e 
Onset of glial activation Cortex and thalamus (3 months)a Cortex and thalamus (3 months)d Cortex and thalamus (1 month)e  
Onset of myelination defects Cortex (3 months)e Cortex (1 month)d Cortex (1 month)e 
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young age. It is likely that neuron loss would become far more
pronounced if these mice were to survive longer, especially given the
profound nature of the exacerbated glial response they display.
In our study, no significant thinning of Cln1/5 cortex was seen
at the age of 3 months. However, Cln5 ko mice did display a
significantly increased thickness in the S1BF, M1 and V1 at this
age. Similar findings have been reported previously by von Schantz
et al., showing increased thickness in the superficial laminae I-III
of 12-month-old Cln5 ko mice (von Schantz et al., 2009). Similarly,
regional volume measurements revealed no atrophy in Cln1/5 dko
brain at the age of 3 months, whereas increased volumes were
observed in 3-month-old Cln5 ko cortex and hippocampus.
Altered lipid and lipoprotein plasma profile in Cln1/5 dko mice
Previous studies have shown that cholesterol metabolism is
disturbed in Cln1 ko mice (Ahtiainen et al., 2007; Lyly et al., 2008),
and more recent studies have indicated even more prominent
aberrations in the systemic lipid homeostasis of Cln5 ko mice
(Schmiedt et al., 2012). In this study, we conducted plasma lipid
profiling of Cln1/5 dko mice and observed significantly elevated
levels of phospholipids and increased PLTP activity in these mice.
These lipid changes were accompanied by the differential
distribution of phospholipids and cholesterol in HDL particles.
Although the previously published results of plasma lipid analyses
of single ko mice were not completely replicated in this study, it is
clear that both Cln1 and Cln5 ko mice show changes in lipid
metabolism. Embryonic neurons of Cln1 ko mice show highly
upregulated synthesis of cholesterol without cholesterol
accumulation (Ahtiainen et al., 2007). They also show increased
plasma membrane expression of the α- and β-subunits of the F1
complex of the mitochondrial ATP syntase, suggested to function
as an apoA-1 receptor (Lyly et al., 2008). Cultured Cln5 ko
macrophages show increased cholesterol efflux as well as changes
in sphingolipid trafficking (Schmiedt et al., 2012). In this study,
possible changes in lipid metabolism were not assessed at the cellular
level. However, plasma lipid changes seen in Cln1/5 dko mice
resemble the trends previously observed in Cln5 ko mice, whereas
Cln1 ko mice seem to display the opposite changes involving
decreased plasma cholesterol (Lyly et al., 2008) (and this study).
Myelin membrane is mainly composed of lipids and is especially
enriched in cholesterol, galactolipids and glycosphingolipids
(Chrast et al., 2011) and is therefore sensitive to disturbed lipid
metabolism. NCL proteins have been suggested to play a role not
only in lipid metabolism/transport but also in myelination processes
(Schmiedt et al., 2012; Kuronen et al., 2012). Myelination was also
affected in this study, as demonstrated by the finding that at the
age of 3 months all three mutant mouse models showed fewer MBP-
positive fibers in the superficial laminae of S1BF compared with
wild-type controls. Although lipid metabolism was not studied in
the brain in this study, we postulate that the disturbances in lipid
metabolism might affect the assembly of the myelin sheath, leading
to defective myelination.
Gene expression profiling of the Cln1/5 dko cortex implicates
changes in genes involved in immune response, nerve
ensheathment and transmission of nerve impulse
Gene expression profiling of the Cln1/5 dko mouse cortex revealed
changes in genes involved particularly in immune response, nerve
ensheathment and transmission of nerve impulse. Consistent with
our immunohistochemical analyses, which indicated defective
myelination in the superficial cortical laminae, downregulation of
key genes in myelin assembly (Opalin, Mal, Mag, Mog, Plp1 and
Mbp) was observed. These gene expression changes might be
indicative of defects in oligodendrocyte development and function.
Furthermore, recent studies have indicated that Cln5 has a specific
role in oligodendrocyte maturation (Schmiedt et al., 2012), and it
is possible that these NCLs share both neurodevelopmental and
neurodegenerative aspects.
Interestingly, the most downregulated gene in the gene
expression data was α-synuclein (Snca), which is upregulated in
many neurodegenerative diseases, such as Parkinson disease
(Vekrellis et al., 2011). Snca was also shown to be upregulated in
Cln1 ko embryonic neuronal cell cultures (Ahtiainen et al., 2007).
The level of soluble α-synuclein was also significantly reduced in
another mouse model of NCL diseases, cathepsin D knockout mice,
where the reduced neuropil staining was accompanied by
aggregation of α-synuclein in inclusion bodies (Cullen et al., 2009).
α-Synuclein is a presynaptic protein and is an important regulator
in dopaminergic transmission, synaptic plasticity and vesicle
trafficking (Uversky, 2008; Ruipérez et al., 2010). α-Synuclein-
deficient mice are viable, but they suffer from significant
neurochemical, electrophysiological and behavioral deficits
(Abeliovich et al., 2000). Western blot analysis supports these
microarray findings, showing almost complete lack of α-synuclein
expression in the cerebral cortex of 1- and 3-month-old Cln1/5
dko mice. Although immunohistological staining showed individual
variability in the levels of α-synuclein protein in 1- and 3-month-
old Cln1/5 dko mice, these results support the western blot
findings, showing reduced α-synuclein staining in the cortex and
slightly decreased expression in the hippocampus. We suggest that
the individual variability might depend on the stage of the disease,
and the loss of α-synuclein expression in cortex could be linked to
the early neuronal loss seen in this region in Cln1/5 dko mice. α-
synuclein might possibly have a role in NCL pathogenesis, or at
least these disease mechanisms might have a significant impact on
α-synuclein expression. This protein also functions as a lipid-
binding protein, and lipids can regulate its oligomerization into
amyloid fibrils found in Lewy bodies (Chua and Tang, 2011).
Among the most upregulated genes in Cln1/5 dko mice were
Cap1; complement C1q subcomponents C1qb and C1qc; and
GFAP. Cap1 has been implicated in a number of complex
developmental and morphological processes, including endocytosis
and actin polymerization (Sultana et al., 2005). Upregulation of
Cap1 was evident in all three knockout models (Cln1 ko, Cln5 ko
and Cln1/5 dko), and it is clustered on the same chromosomal
region as Ppt1 (gene mutated in Cln1 ko), indicating a possible
functional relationship between these genes (Ahtiainen et al., 2007;
von Schantz et al., 2008). C1q, a key player in the classical
complement pathway, is considered to be a marker for microglial
activation (Färber et al., 2009) and is implicated in the pathogenesis
of many neurodegenerative diseases (Nayak et al., 2010).
Furthermore, it has been suggested that in the early stages of CNS
neurodegenerative diseases, reactive astrocytes and C1q play a role
in pathophysiological process that leads to synapse loss and
neuronal death (Stevens et al., 2007). Indeed, the upregulation of
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in Cln1/5 dko brains. Our gene expression data provide further
insight into the processes involved in the early stages of NCL
pathogenesis. Upregulation of immune response pathways is
consistent with the microglial activation we observed in the affected
cerebral cortex. Decreased expression of myelin-specific genes
provides evidence that defective myelination is due to a failure in
myelin development processes. We suggest that NCL proteins are
linked to the development of the nervous system or involved in as-
yet uncharacterized neuron-specific metabolic pathways.
Conclusions
Simultaneous deletion of two NCL genes, Cln1 and Cln5, has
allowed us to show for the first time that early demyelination,
cortical astrocytosis and microglial activation all occur prior to
neuronal loss in this model. Because the loss of both Cln1 and Cln5
genes led to a more severe NCL phenotype in mice than the loss
of only one of these genes, these results could be interpreted as
further support for the existence of interactions between Cln1 and
Cln5 gene products. Alternatively, this could simply reflect that
deficiency of these genes leads to convergent pathological pathways
that have a more severe combined effect. Indeed, significant
accumulation of autofluorescent storage material, the ultrastructure
of storage material, increased astrocytosis and microglial activation,
as well as myelination defects seen in Cln1/5 dko mice resemble
the more severe pathological features of Cln1 ko mice, whereas the
onset of neuron loss is similar to that observed in Cln5 ko mice.
Decreased α-synuclein gene and protein expression in the Cln1/5
dko brain is a new finding that might reflect the early cortical
neuron loss and needs further investigation. More detailed studies
are needed to obtain a comprehensive view of NCL diseases and
the neurodegenerative mechanisms involved in the development
of these brain disorders.
MATERIALS AND METHODS
Generation of the Cln1/5 dko mouse model
Homozygous Cln1−/− (Cln1 ko) and Cln5−/− (Cln5 ko) mice (Mus
musculus) were backcrossed to C57BL/6JRccHsd for more than ten
generations, and their congeneity was confirmed with the Mouse
Medium Density SNP Panel (Illumina). Cln1 ko and Cln5 ko mice
were crossed to initially generate heterozygous and, subsequently,
Cln1−/−/Cln5−/− double-knockout (Cln1/5 dko) offspring. These
Cln1/5 dko offspring were viable and fertile. The genotypes of the
mice were determined by PCR of DNA from tail biopsies. We used
systematically sampled brain or skin tissue from E16.5 to 3-month-
old mice, with age- and sex-matched C57BL/6JRcc wild-type mice
serving as a control strain. After sacrificing, body weight was
determined.
All animal procedures were performed according to protocols
approved by the ethical boards for animal experimentation of the
National Public Health Institute and University of Helsinki, as well
as State Provincial offices of Finland (agreement numbers ESLH
2009-05074/STH 415 A and KEK10-059). All experiments were
performed in accordance with good practice of handling laboratory
animals and genetically modified organisms.
Generation and characterization of murine iPS cells
Mouse embryonic fibroblasts (MEFs) from both the Cln1/5 dko
and wild-type mice (E16.5) were reprogrammed by using the
retrovirus-mediated delivery of the four Yamanaka factors (Oct-
3/4, Sox-2, Klf-4 and c-Myc; Addgene plasmids 13366, 13367, 13370
and 13375) (Kitamura et al., 2003) according to a published
protocol (Takahashi et al., 2007). iPS cell clones were grown on
leukemia inhibitory factor (LIF)-producing SNL-feeder cells
(McMahon and Bradley, 1990), kindly provided by the Wellcome
Trust Sanger Institute (UK), collected on the basis of colony
morphology (supplementary material Fig. S1A), expanded and
further purified by MACS anti-stage-specific embryonic antigen 1
(SSEA-1) MicroBeads (Miltenyi Biotech, Bergisch Gladbach,
Germany). Expression of SSEA-1 (supplementary material Fig. S1A)
and alkaline phosphatase (data not shown) in different clones was
analyzed by ES cell characterization kit (Millipore, Billerica, MA).
Expression of other ES cell marker genes (Nanog, Rex-1, Fgf-4, Esg-
1 and E-ras) in selected iPS cell clones was verified by RT-PCR
(supplementary material Fig. S1B) by using primer sequences earlier
described (Takahashi et al., 2007).
EB formation and analyses of EB size
To minimize the inhibitory effect of the remaining feeder cells
during EB formation, all iPS cell clones were purified by MACS
anti-SSEA-1 MicroBeads (Miltenyi Biotech) before starting the
experiments. The number of purified cells was analyzed by
Nexcelom T4 cell counter (Nexcelom Bioscience, Lawrence, MA)
and 1.5×106 cells/clone were plated on 60-mm Petri dishes (Sterilin,
Newport, UK) to facilitate EB growth in suspension in ES medium
(DMEM+15% ES serum, 1× Glutamax, 0.1 mM non-essential
amino acids, 0.1 mM 2-mercaptoethanol and antibiotics).
Formation of EBs was followed daily by microscope. On day seven,
EBs were transferred onto 12-well plates for recording images with
a Leica EC3 digital camera attached to Leica DMIL microscope
(Leica Microsystems, Wetzlar, Germany). The size of EBs was
determined by the Las EZ program (Leica Microsystems). The
average size of EBs derived from different iPS cell clones was
calculated from minimum of 40 different EBs. Statistical analyses
of the difference in EB size between Cln1/5 dko and wild-type
clones were assessed using the Student’s t-test for independent
samples, with unequal variances assumed. Statistical significance
was considered at P<0.05; P-values are two-sided. Results are
presented as means and s.e.m. EB formation was always done in
pairs with Cln1/5 dko and wild-type clones. Results were verified
in three independent experiments (by using three Cln1/5 dko and
two wild-type clones).
Differentiation of iPS cells into different germ layers
To study the spontaneous differentiation potential of the produced
iPS cell clones into the three primary germ layers, EBs were grown
as described above for 7 days and then plated on gelatin-coated
tissue culture plates. Differentiation was followed daily by
microscope. The cells were fixed with 4% paraformaldehyde (PFA)
and stained with goat anti-FoxA2 (1:100, Santa Cruz
Biotechnology, Santa Cruz, CA), rabbit anti-β-III tubulin (1:1000,
Covance, Princeton, NJ) or rabbit anti-desmin (1:500, Epitomics,
Burlingame, CA) antibodies for indication of endoderm, ectoderm
and mesoderm, respectively (supplementary material Fig. S2).
Image processing (brightness and contrast) was performed with
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Electron microscopy and autofluorescence of storage material
For electron microscopy, the brains were removed from sacrificed
3-month-old male Cln1 ko, Cln5 ko and Cln1/5 dko mice and wild-
type controls. Bisected brains were immersion fixed in 0.1 M
phosphate buffer pH 7.4 containing 4% PFA and 2.5% glutaraldehyde
for 2 hours, incubated in fresh fix solution for 2 days, and stored in
10 mM phosphate buffer at +4°C until processed further. Pieces of
1-2 mm3 were excised from corpus callosum, thalamus, brain stem
and cerebral cortex. Pieces were osmicated, dehydrated and
embedded in epoxy resin. After identification of the desired
anatomical regions from thin sections stained with toluidine blue,
ultrathin sections were cut and contrasted with uranyl acetate and
lead citrate and viewed by JEOL 1400 transmission electron
microscope (JEOL, Tokyo, Japan). Images were taken with an
Olympus-SIS Morada camera (Olympus, Tokyo, Japan).
For autofluorescence analysis, Cln1 ko, Cln5 ko, Cln1/5 dko and
wild-type mice were perfused with 4% PFA, and the brains were
further immersion fixed in 4% PFA. Mouse brain sections spanning
the S1BF and VPM/VPL were mounted onto gelatin-chrome-coated
slides and cover-slipped with Vectashield (Vector Laboratories,
Peterborough, UK). Images from each section were captured at 63×
magnification using a Leica SP5 confocal microscope and a 488
nm excitation laser (Leica Microsystems). Thresholding image
analysis was performed to determine the extent of endogenous
autofluorescence. Three animals per group were included in the
analysis. Three consecutive sections spanning the S1BF or
VPM/VPL were mounted onto a chrome-gelatin-coated slide and
cover-slipped. The non-overlapping images from each section
were captured at 40× magnification using a Leica SP5 confocal
microscope and a 488 nm excitation laser. During image capture,
all parameters and calibration were kept constant. Semi-
quantitative thresholding image analysis was carried out using
Image Pro Plus software (Media Cybernetics, Chicago, IL) to
determine the number of pixels per image that contained
autofluorescent storage material.
Histological processing and Nissl staining
Brains from 3-month-old Cln1 ko, Cln5 ko and Cln1/5 dko male
mice and wild-type controls (n6 per genotype) were harvested as
previously described (Schmiedt et al., 2012). Briefly, the mice were
perfused with 4% PFA, and the brains were removed and postfixed
in 4% PFA in 0.1 M sodium phosphate buffer (pH 7.4) overnight
before cryoprotection in 30% sucrose in 50 mM Tris-buffered saline
(TBS) with 0.05% sodium azide, and then frozen in liquid nitrogen
and stored at –80°C. The brains were bisected along the midline
and cut into 40-μm frozen coronal sections (Microm freezing
microtome, Thermo Fisher Scientific, Waltham, MA). A series of
every sixth section through each brain was mounted onto gelatin-
chrome-coated Superfrost microscope slides (VWR, Radnor, PA).
Slides were air-dried overnight and incubated with 0.05% cresyl
fast violet and 0.05% acetic acid (VWR) in water for 45 minute at
60°C, rinsed in distilled water and differentiated through an
ascending series of alcohols, cleared in xylene and cover-slipped
with DPX (VWR).
Immunohistochemistry of frozen sections
To investigate the extent of astrocytosis, microglial activation and
myelination in 1- and 3-month-old male Cln1 ko, Cln5 ko, and
Cln1/5 dko and the wild-type control brains (n6 per genotype),
a one in six series of free-floating frozen sections were
immunohistochemically stained for GFAP, cluster of differentiation
(CD68) and myelin basic protein (MBP), respectively [as described
previously (von Schantz et al., 2009; Schmiedt et al., 2012)]. Briefly,
sections were incubated in 1% hydrogen peroxide (H2O2) in TBS
and blocked for 40 minutes with TBS containing 0.3% Triton X-
100 (TBST) and 15% normal goat serum before incubation
overnight in the following polyclonal primary serums: rabbit anti-
GFAP (1:4000; DAKO, Glostrup, Denmark), rat anti-CD68 (1:1000;
Serotec, Oxford, UK), and rat anti-MBP (1:500; Millipore) diluted
in TBS with 10% normal rabbit or rat serum and TBST. Sections
were incubated for 2 hours with secondary antiserum (biotinylated
goat anti-rabbit IgG (1:1000; Vector Laboratories) in TBS with 10%
normal goat serum and TBST, and for 2 hours in an avidin-biotin-
peroxidase complex in TBS (Vectastain ABC Elite Kit, Vector
Laboratories). Immunoreactivity was visualized by 0.05% 3,3′-
diaminobenzidine tetrahydrochloride (DAB) (Sigma-Aldrich, St
Louis, MO) and 0.001% H2O2 in TBS for 10 minutes. Sections were
mounted on gelatin-chrome-coated Superfrost microscope slides
(WVR), and cover-slipped with DPX.
Thresholding image analysis of astrocytic and microglial
phenotypes
The optical density of GFAP and CD68 immunoreactivity was
assessed using semi-automated thresholding image analysis, as
previously described (Bible et al., 2004; Pontikis et al., 2005). Three
animals per group were included in the analysis. Briefly, 30 non-
overlapping images, on triplicate sections, were taken through the
thalamic VPM/VPL and cortical S1BF regions, starting from a
defined anatomical landmark. Images were captured with Leica SP5
confocal microscope using a 40× objective. Image Pro Plus image
analysis software (Media Cybernetics) was used to determine the
area of immmunoreactivity by applying a threshold that
discriminated staining from background in each image. Data were
separately plotted graphically as the mean percentage area of
immunoreactivity per field ± s.e.m. for each region. Differences
between groups were analyzed with one-way ANOVA (more than
two groups) with post-hoc Bonferroni. The level of significance was
set to P<0.05.
Immunohistochemistry of paraffin sections
α-synuclein protein expression was analyzed from paraffin sections.
Three-month-old male Cln1 ko, Cln5 ko, Cln1/5 dko and wild-type
control mice (n6 per genotype) were included in the study. Brains
were removed, bisected along the midline and immersion fixed with
4% PFA in PBS (pH 7.4) before embedding in paraffin. The tissue
sections were cut into 5-μm sections and stained with α-synuclein
antibody (rabbit polyclonal hSA-2, raised and affinity-purified at
Open Biosystems, Huntsville, AL) against recombinant, full-length
α-synuclein. The antibody was a kind gift from Prof. Michael G.
Schlossmacher, University of Ottawa, Canada, and is described in
the literature (Mollenhauer et al., 2008). Briefly, sections were
deparaffinized, rehydrated in alcohol series, incubated in 5% H2O2
in methanol to quench endogenous peroxidase activity and rinsed
with TBS. After boiling in citrate buffer (pH 6.0) for 5 minutes, the
sections were blocked with 10% goat serum in TBS and incubated
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1:800) in 10% goat serum in TBS. Sections were washed with TBST
(0.025%) and incubated with biotinylated secondary antibody (anti-
rabbit IgG, 1:200; Jackson ImmunoResearch Laboratories, Reston,
VA) in 10% goat serum in TBS for one hour. Sections were treated
with avidin-biotin peroxidase mix (Vectastain ABC Elite Kit, 1:400;
Vector Laboratories) for 40 minutes followed by washes with TBS.
Antibody binding was detected with a standard DAB reaction
(Sigma-Aldrich), after which the sections were counterstained for
two minutes with hematoxylin (Sigma-Aldrich). After dehydration,
the sections were cleared in xylene, air-dried and cover-slipped with
DPX.
Measurements of cortical thickness and regional volume
Stereological analysis was used to determine the thickness of the
M1, S1BF, V1 and LEnt cortical layers, as well as cortical and
hippocampal volumes. We used StereoInvestigator software
(Microbrightfield, Williston, VT) to obtain unbiased Cavalieri
estimates from 40-μm Nissl-stained cryosections from Cln1 ko,
Cln5 ko, Cln1/5 dko and wild-type male mice (n6 per genotype)
at 3 months of age, with no prior knowledge of genotype. The
boundaries of brain regions were defined by reference to landmarks
described by Paxinos and Franklin (Paxinos and Franklin, 2001).
All analyses were carried out on a Zeiss, Axioskop 2 MOT
microscope (Carl Zeiss, Welwyn Garden City, UK) linked to a
DAGE-MTI CCD-100 camera (DAGE-MTI, Michigan City, IN).
Measurements of the thickness of M1, S1BF, V1 and LEnt were
made in three consecutive Nissl-stained sections with ten
measurements made from the white matter to the pial surface of
the cortex within each section (Bible et al., 2004). Results were
expressed as the mean cortical thickness (micrometers per region).
Regional volumes of cortex and hippocampus were determined by
placing an appropriately spaced sampling grid over sections and
the number of points covering the relevant areas was assessed using
a 2.5× objective. Results are expressed in cubic micrometers and
the mean volume of each region was calculated for each genotype.
The mean coefficient of error (CE) for all individual Cavalieri
estimates was calculated according to the method of Gundersen
and Jensen (Gundersen and Jensen, 1987) and was ≤0.1 in all these
analyses. Differences between groups were analyzed with one-way
ANOVA with post-hoc Bonferroni (GraphPad Software, La Jolla,
CA). The level of significance was set to P<0.05.
Counts of neuronal number
The design-based optical fractionator probe was used to estimate
cell number in Nissl-stained sections in cortical S1BF and
VPM/VPL. Nissl-stained cells were only counted if they had a
neuronal morphology and a clearly identifiable nucleolus. A line
was traced around the boundary of the region of interest, a grid
was superimposed and cells were counted using a 100× objective
within a series of dissector frames placed according to intersections
of the sampling grid. Different grid and dissector sizes were
determined according to each brain region using a CE value ≤0.1
to indicate sampling efficiency. Layer V of the S1BF grid was
175×175 μm, frame 70×40 μm; layer VI grid was 200×175 μm, frame
55×40 μm; and layer IV grid was 150×150 μm, frame 70×40 μm.
For VPM/VPL, the grid was 175×175 μm, frame 70×40 μm. A series
of every sixth Nissl-stained sections was used for all the brain
regions. Differences between groups were analyzed with one-way
ANOVA (more than two groups) with post-hoc Bonferroni. The
level of significance was set to P<0.05.
Plasma lipid analysis
Female 1-month-old Cln5 ko, Cln1 ko and Cln1/5 dko mice (n8
per genotype) and wild-type controls were fasted for a 4-hour
period and blood taken for plasma lipid and lipoprotein analysis.
Iodoacetic acid (1 mM final) was immediately added to samples to
avoid lecithin-cholesterol acyltransferase (LCAT) activity.
Triglycerides and total cholesterol were measured using enzymatic
methods (GPO-PAP 1488872 kit and CHOD-PAP 1489232 kit,
respectively; Roche Diagnostics, Basel, Switzerland). Mouse apoA-
1 was quantified by sandwich ELISA (van Haperen et al., 2000) and
PLTP activity measured using radiometric assay (Jauhiainen and
Ehnholm, 2005). For the analysis of cholesterol distribution in
lipoproteins, plasma samples were pooled and fractionated by fast-
performance liquid chromatography (FPLC) using high-resolution
Superose 6 size-exclusion chromatography columns (GE
Healthcare, Waukesha, WI) to separate the lipoprotein classes. Two
pools per genotype (wild-type, Cln5 ko, Cln1 ko and Cln1/5 dko)
were analyzed (three independent plasma samples per genotype).
P-values were evaluated using one-way ANOVA, with P<0.05
considered as statistically significant.
Gene expression profiling
Comparative gene expression profiling was performed from the 1-
month-old Cln1/5 dko male mice and wild-type controls (n6 per
genotype). Cortices from the left hemisphere of wild-type controls
and Cln1/5 dko mice were excised and the RNA isolated with
Qiagen RNA Lipid Tissue Kit (Qiagen, Hilden, Germany). Purity
of RNA was verified with Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA) and its concentration was
determined with NanoDrop (Thermo Fisher Scientific). Total RNA
in a 400 ng sample was labeled and fragmented. Hybridization, post-
hybridization washes, staining and scanning were performed
according to the manufacturer’s instructions (Applied Biosystems,
Foster City, CA). Gene expression profiles were determined using
the Illumina MouseWG-6 v2.0 Expression BeadChip and
GenomeStudio Data Analysis Software (Illumina, San Diego, CA).
Gene expression analysis was performed with Chipster v1.4.7
analysis software (CSC, Espoo, Finland), and data normalization
was carried out using the quantile method. Quality control was
performed to ensure the technical quality of the samples. P-values
(adjusted with conditional testing) were used to determine the
significantly up- and downregulated genes (P<0.05). Pathway
analysis from the up- or downregulated genes (according to
Student’s t-test, P<0.05) was performed with DAVID Bioinformatics
Resources 6.7 software (Huang et al., 2009a; Huang et al., 2009b),
and the Benjamini-Hochberg method was used for multiple
hypothesis testing correction of the P-values.
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR was performed as described
previously (Schmiedt et al., 2012). Briefly, RNA from frozen cortices
of 1-month-old Cln1/5 dko (n6) and wild-type control (n6) mice
was isolated as described in the previous paragraph. RNA was
treated with DNase I (Qiagen) in order to eliminate genomic DNA.
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RNA using TaqMan Reverse Transcription Reagents with random
hexamer primers (Applied Biosystems, Foster City, CA). To average
out the inter-individual variability, three different reverse
transcription reactions were performed for each sample. TaqMan
Gene Expression Array of selected genes was purchased from
Applied Biosystems (Snca: Mm01188700_m1). The mRNA
expression levels of this gene and a standard house-keeping gene,
mouse TATA-box binding protein (Tbp: Mm00446970_m1), were
quantified with ABI Prism 7000 sequence detection system
(Applied Biosystems). The PCR reactions (10 μl) were carried out
with TaqMan Universal Master Mix according to manufacturer’s
instructions using the following parameters: 50°C for 2 minutes,
95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for
1 minutes. Relative levels of the selected genes were calculated using
the ΔΔCT method, as described previously (Kopra et al., 2004). The
absolute change in expression level is given by 2–ΔΔCT.
Western blotting
Whole brains without cerebellum (denoted as ‘cerebrum’) and
cortices of 1- and 3-month-old Cln1 ko (n3), Cln5 ko (n3), Cln1/5
dko (n5) and wild-type control (n4) mice were homogenized in
extraction buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 5 mM
MgCl2, 0.5% Triton X-100) supplemented with Protease Inhibitor
Cocktail (Sigma-Aldrich) using Precellys CK14 lysing tubes (Bertin
Technologies, France). The homogenates were clarified by
centrifugation at 1000 g for 10 minutes in a Beckman TLA 100.3
rotor at +4°C. Total protein concentrations were estimated by DC
Protein Assay (Bio-Rad, Hercules, CA) and equal amounts of total
protein (30 μg) were analyzed by western blotting. Protein samples
were boiled and run on a 14% SDS-PAGE gel. After the transfer to
nitrocellulose membrane (Hybond ECL, GE Healthcare), the blot
was blocked in 5% milk powder in TBST and incubated with
primary antibody (mouse-anti-α-synuclein, 1:1000; Cell Signaling,
Danvers, MA) followed by the incubation with HRP-conjugated
goat-anti-mouse secondary antiserum (1:5000; DAKO).
Immunoreactivity was visualized by enhanced chemiluminescence
assay (Western Lightning-ECL, PerkinElmer, Waltham, MA). β-III
tubulin (1:1000; Millipore) expression was used as a loading control.
Densitometric analysis of the autoradiograms was performed using
NIH ImageJ 1.41o software. Student’s t-test was used for the
statistical analyses. Three animals per group were included in the
analysis.
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